MediWound Ltd.
NASDAQ:MDWDBiotechnology
-$0.09 today
- Market cap
- $175.71M
- Beta
- 0.15
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$2.03
Volume 0.17M
Average 0.09M
MDWD Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
MediWound Ltd.NASDAQ: MDWD
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 46.9% from a year ago
Net receivables stood at $2.75M at the end of Q1 FY2026, down 46.9% from a year earlier and up 15.9% from the prior quarter. Over 3 fiscal years it compounded at -37.5% a year.
Context
- Net receivables amounted to 3.4% of total assets at the end of Q1 FY2026, down 4.1 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -46.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 2.37M USD
- Year-over-year change
- -59.5%
- 4-year CAGR
- +1.1%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.37M | -59.5% |
| FY2024 | 2024-12-31 | 5.85M | +32.4% |
| FY2023 | 2023-12-31 | 4.42M | -54.4% |
| FY2022 | 2022-12-31 | 9.7M | +327.7% |
| FY2021 | 2021-12-31 | 2.27M | — |
Net Receivables vs competitors
How MDWD compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -46.9% is the 6th highest of 7, against a peer median of +16.9%.
- Net receivables amounts to 3.4% of total assets for MDWD, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $12.21M USD | +39.5% | +238.3% | 5.1% | |
| Dec 2025 | €9.12M EUR | -25.0% | +219.7% | 3.7% | |
| Mar 2026 | $2.75M USD | -46.9% | -37.5% | 3.4% | |
| Mar 2026 | $1.52M USD | +312.2% | +37.3% | 0.8% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $665.42K USD | +179.0% | — | 0.5% |
| Mar 2026 | $261K USD | -85.2% | -51.6% | 0.1% | |
| Mar 2026 | $138.25K USD | — | — | 4.2% | |
| Mar 2026 | $84K USD | -5.6% | -0.3% | 0.1% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MDWD) | — | +16.9% | +37.3% | 0.5% | |
Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11.05M | 33.9M | 11.87M | 9.16M | 4.8M |
| Short-term Investments | 0 | 0 | 29.68M | 34.01M | 48.34M |
| Net Receivables | 2.27M | 9.7M | 4.42M | 5.85M | 2.37M |
| Inventory | 1.2M | 1.96M | 2.85M | 2.69M | 4.09M |
| Other Current Assets | 0 | 363K | 167K | 0 | 0 |
| Total Current Assets | 14.95M | 45.84M | 49.7M | 52.16M | 59.96M |
| Property, Plant & Equipment (Net) | 4.03M | 3.58M | 15.93M | 20.8M | 25.79M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 297K | 231K | 165K | 99K | 33K |
| Long-term Investments | 469K | 364K | 490K | 439K | 467K |
| Tax Assets | (469K) | (364K) | 0 | 0 | 0 |
| Other Non-current Assets | (4.32M) | (3.81M) | 183K | 0 | 0 |
| Total Non-current Assets | 4.79M | 4.18M | 16.76M | 21.33M | 26.29M |
| Total Assets | 19.74M | 50.02M | 66.46M | 73.5M | 86.26M |
| Account Payables | 4.69M | 5.66M | 4.22M | 4.1M | 3.61M |
| Short-term Debt | 0 | 0 | 0 | 418K | 623K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 543K | 63K | 24K | 12K | 0 |
| Other Current Liabilities | 3.85M | 3.87M | 1.86M | 17.73M | 18.43M |
| Total Current Liabilities | 10.72M | 12.06M | 10.83M | 26.54M | 25.71M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 119K | 0 | 0 | 736K | 0 |
| Other Non-current Liabilities | 12.1M | 26.2M | 10.39M | 8.55M | 472K |
| Total Non-current Liabilities | 13.61M | 27.05M | 16.74M | 15.8M | 8.62M |
| Total Liabilities | 24.33M | 39.1M | 34.86M | 42.34M | 34.33M |
| Common Stock | 75K | 143K | 184K | 215K | 258K |
| Retained Earnings | (148.51M) | (168.11M) | (174.82M) | (205.05M) | (228.93M) |
| Accumulated OCI | (19K) | (5K) | (18K) | (11K) | (32K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (4.58M) | 10.91M | 31.6M | 31.15M | 43.63M |
| Total Debt | 1.39M | 846K | 6.35M | 6.93M | 8.77M |
| Net Debt | (9.66M) | (33.05M) | (5.52M) | (2.22M) | 3.98M |
MediWound Ltd.
NASDAQ:MDWD
Intrinsic Alpha fair value
Locked
Current Price
$13.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.